Introduction Sodium–glucose co-transporter 2 (SGLT2) inhibitors exert plasma glucose-lowering effects via urinary glucose excretion. Recent clinical trials have shown the various beneficial effects of SGLT2 inhibitors, including reductions in
Page:12
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Yuka Goto, Yoshie Otsuka, Kenji Ashida, Ayako Nagayama, Nao Hasuzawa, Shimpei Iwata, Kento Hara, Munehisa Tsuruta, Nobuhiko Wada, Seiichi Motomura, Yuji Tajiri, and Masatoshi Nomura
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Merlin C Thomas, Brendon L Neuen, Stephen M Twigg, Mark E Cooper, and Sunil V Badve
enormous health, societal and economic burden associated with CKD demands that some priority should be given to the prevention and treatment of CKD in people with T2D. Sodium‐glucose co-transporter 2 (SGLT2) inhibitors have recently emerged as an
Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
Katrine M Lauritsen, Jens Hohwü Voigt, Steen Bønløkke Pedersen, Troels K Hansen, Niels Møller, Niels Jessen, Lars C Gormsen, and Esben Søndergaard
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic agents with remarkable cardiovascular benefits ( 1 ). Even though SGLT2 inhibitors primarily exert their pharmacological effect in the kidneys, the
The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
Zeeshan Javed, Maria Papageorgiou, Leigh A Madden, Alan S Rigby, Eric S Kilpatrick, Stephen L Atkin, and Thozhukat Sathyapalan
treatment with exenatide resulted in reductions in serum ICAM-1, p-selectin and e-selectin, although no pronounced changes were seen in endothelial function ( 25 ). Empagliflozin is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor used in the treatment
Effect of COVID-19 on the clinical course of diabetic ketoacidosis (DKA) in people with type 1 and type 2 diabetes
Punith Kempegowda, Eka Melson, Agnes Johnson, Lucy Wallett, Lucretia Thomas, Dengyi Zhou, Catherine Holmes, Agata Juszczak, Mohammed Ali Karamat, Sandip Ghosh, Wasim Hanif, Parth Narendran, and Srikanth Bellary
negative (eight T1DM, three T2DM), and one pre-COVID (T2DM) had hypertension as a comorbidity. Six patients in COVID-positive and one person in COVID-negative group were on SGLT2 inhibitors; none of the people in the pre-COVID period were on this class of
Frequency and characteristics of diabetes in lipodystrophies and insulin receptoropathies compared with type 1 and type 2: results from the multicenter DPV registry
Clemens Kamrath, Alexander Eckert, Birgit Rami-Merhar, Sebastian Kummer, Martin Wabitsch, Katharina Laubner, Florian Kopp, Silvia Müther, Steffen Mühldorfer, and Reinhard W Holl
.0 4.0 4.8 ns ns 0.002 ns SGLT2 inhibitors 0.3 4.5 4.0 7.1 ns ns <0.001 ns Lipid-lowering drugs 6.9 28.3 28.0 19.1 0.001 ns ns ns Statins 6.4 26.4 8.0 16.7 ns ns ns ns
Chronic kidney disease in patients with diabetes mellitus
Espen Nordheim and Trond Geir Jenssen
reduced hyperfiltration and improved proteinuria, might also have a role. Promising results were found with the SGLT2-inhibitors early in the cardiovascular safety studies, for example, with empagliflozin (EMPA-REG), canagliflozin (CANVAS) and
Early and late endocrine complications of COVID-19
Paraskevi Kazakou, Stavroula A Paschou, Theodora Psaltopoulou, Maria Gavriatopoulou, Eleni Korompoki, Katerina Stefanaki, Fotini Kanouta, Georgia N Kassi, Meletios-Athanasios Dimopoulos, and Asimina Mitrakou
. Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors AACE Clinical Case Reports 2021 7 10 – 13 . ( https://doi.org/10.1016/j.aace.2020.11.019 ) 52 Fang J Genco M Caskey RN . COVID-19
The changing landscape of automated insulin delivery in the management of type 1 diabetes
Rama Lakshman, Charlotte Boughton, and Roman Hovorka
glycaemic control and potentially reduce the need for carbohydrate counting. Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower plasma glucose by blocking renal reabsorption and increasing the excretion of glucose in the urine. Their use in T1D is
Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties
Ann-Kristin Picke, Graeme Campbell, Nicola Napoli, Lorenz C Hofbauer, and Martina Rauner
2, the key transporter mediating glucose reabsorption by the kidney), thereby increasing urinary glucose excretion ( 164 , 165 ). The first three SGLT2 inhibitors released in the market, namely canagliflozin, empagliflozin and dapagliflozin, have
Page:12
